share_log

PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review

Defense World ·  Apr 17, 2023 14:26

Ocugen (NASDAQ:OCGN – Get Rating) and PharmaCyte Biotech (OTCMKTS:PMCB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Institutional & Insider Ownership

37.5% of Ocugen shares are held by institutional investors. Comparatively, 33.2% of PharmaCyte Biotech shares are held by institutional investors. 2.8% of Ocugen shares are held by insiders. Comparatively, 5.6% of PharmaCyte Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Get Ocugen alerts:

Analyst Recommendations

This is a summary of current recommendations for Ocugen and PharmaCyte Biotech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocugen 0 0 5 0 3.00
PharmaCyte Biotech 0 0 0 0 N/A

Ocugen currently has a consensus price target of $4.80, suggesting a potential upside of 499.85%. Given Ocugen's higher probable upside, research analysts clearly believe Ocugen is more favorable than PharmaCyte Biotech.

Profitability

This table compares Ocugen and PharmaCyte Biotech's net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocugen N/A -76.64% -65.51%
PharmaCyte Biotech N/A -6.71% -6.64%

Earnings and Valuation

This table compares Ocugen and PharmaCyte Biotech's top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocugen $42.62 million 4.25 -$81.35 million ($0.38) -2.11
PharmaCyte Biotech N/A N/A -$4.24 million ($0.26) -11.35

PharmaCyte Biotech has lower revenue, but higher earnings than Ocugen. PharmaCyte Biotech is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Ocugen has a beta of 3.85, suggesting that its share price is 285% more volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500.

Summary

Ocugen beats PharmaCyte Biotech on 6 of the 11 factors compared between the two stocks.

About Ocugen

(Get Rating)

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

About PharmaCyte Biotech

(Get Rating)

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment